Omega-3 fatty acids — specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — are among the most studied nutrients in clinical medicine. The evidence file is enormous: thousands of randomized controlled trials, hundreds of meta-analyses, and clinical guidelines from every major cardiology and nutrition organization worldwide. A 2020 Mayo Clinic Proceedings meta-analysis (40 RCTs, n=135,267, led by Dr. Aldo Bernasconi) confirmed a 13% reduction in heart attack risk with EPA+DHA supplementation above 1 g/day, with greater benefit at higher doses. Yet omega-3s also represent one of the most confusing supplement categories for consumers — the differences between EPA and DHA, between fish oil and algae oil, between dietary and therapeutic doses, and between the forms on the supplement shelf all matter clinically but are rarely explained clearly.
EPA, DHA, and ALA: Not the Same Thing
The term "omega-3" refers to a family of polyunsaturated fatty acids that share a chemical structure: a double bond at the third carbon from the methyl end of the fatty acid chain. Three omega-3s matter nutritionally: ALA (alpha-linolenic acid, found in flaxseed, chia seeds, and walnuts), EPA (eicosapentaenoic acid, found in fatty fish and algae), and DHA (docosahexaenoic acid, also from fatty fish and algae).
ALA is the plant-based omega-3 that most vegetarians and vegans rely on. The problem: the body must convert ALA to EPA and DHA to achieve the cardiovascular and neurological effects demonstrated in clinical trials, and the conversion rate is extremely poor — approximately 5–10% for EPA and less than 1% for DHA, according to Dr. Philip Calder, professor of nutritional immunology at the University of Southampton and one of the most cited omega-3 researchers. A tablespoon of flaxseed oil (7 g ALA) produces roughly 350–700 mg of EPA and less than 70 mg of DHA — far below therapeutic doses. ALA has its own modest benefits (associated with reduced cardiovascular risk in observational studies), but it is not a functional substitute for EPA and DHA supplementation.
EPA and DHA serve different physiological functions. EPA is primarily anti-inflammatory — it competes with arachidonic acid for the COX and LOX enzyme pathways, reducing the production of pro-inflammatory eicosanoids. DHA is primarily structural — it comprises roughly 40% of polyunsaturated fatty acids in the brain and 60% in the retina, and is essential for neuronal membrane fluidity and synaptic function. Both are important, but clinical trials increasingly suggest that EPA drives the cardiovascular benefits while DHA drives the neurological benefits.
The Cardiovascular Evidence: From Mixed to Clear
Dr. William Harris, professor at the Sanford School of Medicine at the University of South Dakota and co-inventor of the Omega-3 Index, has spent three decades building the evidence base for omega-3s and cardiovascular risk. His foundational observation: a blood omega-3 level (the Omega-3 Index, measuring EPA+DHA as a percentage of red blood cell membrane fatty acids) above 8% correlates with a 35% reduction in cardiovascular mortality — an effect size comparable to statin therapy.
The field experienced a period of confusion from 2012 to 2018, when several large meta-analyses and trials (including ASCEND, VITAL, and the Cochrane omega-3 review) concluded that omega-3 supplementation had no significant effect on cardiovascular events. Dr. Harris and colleagues argued that these null results reflected inadequate dosing — most trials used 1 g/day of mixed EPA+DHA, which may be too low to meaningfully shift the Omega-3 Index in individuals with low baseline levels.
REDUCE-IT changed the clinical conversation. The 25% reduction in events — including a 31% reduction in heart attack, 28% reduction in stroke, and 20% reduction in cardiovascular death — was achieved on top of statin therapy, establishing EPA as an adjunctive cardiovascular therapy rather than an alternative to statins. The American Heart Association, the European Society of Cardiology, and the American Diabetes Association all updated their guidelines to recommend high-dose EPA for patients with elevated triglycerides despite statin therapy.
A caveat: the STRENGTH trial (2020, JAMA, n=13,078), which tested a combined EPA+DHA formulation at 4 g/day, found no cardiovascular benefit. Whether this reflects a genuine difference between pure EPA and combined EPA+DHA, or a difference in the formulations used (icosapent ethyl vs. carboxylic acid), remains debated. Some researchers, including Dr. Steven Nissen at the Cleveland Clinic (STRENGTH's principal investigator), argue that DHA may partially offset EPA's benefits by raising LDL cholesterol — a small but potentially meaningful effect at high doses.
Triglyceride Reduction
Omega-3s at therapeutic doses (2–4 g combined EPA+DHA daily) produce 15–30% reductions in serum triglycerides, primarily by reducing hepatic VLDL production and increasing triglyceride clearance. This effect is dose-dependent: 1 g/day produces minimal triglyceride reduction; 2 g/day produces approximately 15%; 4 g/day produces 25–30%. The FDA has approved two prescription omega-3 formulations (Vascepa and Lovaza) for severe hypertriglyceridemia (>500 mg/dL), reflecting the strength of the triglyceride-lowering evidence.
Standard dietary supplement doses (500–1,000 mg EPA+DHA) are insufficient for meaningful triglyceride reduction. Consumers who purchase fish oil capsules for cardiovascular benefit and take one standard capsule daily (typically 300 mg EPA+DHA) are receiving a dose that is clinically irrelevant for triglyceride management and marginal for cardiovascular risk reduction.
Brain Health: Prevention vs. Treatment
DHA is the dominant structural fatty acid in the brain, concentrated in synaptic membranes where it maintains the fluidity and flexibility that neurotransmitter signaling requires. The brain's DHA content declines with aging, and low blood DHA levels are associated with accelerated cognitive decline and increased Alzheimer's risk in observational studies.
Dr. Martha Clare Morris at Rush University (developer of the MIND diet) demonstrated in the Rush Memory and Aging Project (n=923, 4.5-year follow-up) that consuming one fish meal per week reduced Alzheimer's risk by 60%. This was an observational finding, but the magnitude of the association — and its consistency across populations and studies — generated considerable interest in DHA supplementation for cognitive protection.
Interventional trials tell a more nuanced story. A 2022 Cochrane Review (k=25 RCTs, n=over 10,000) concluded that omega-3 supplementation in cognitively healthy older adults does not significantly improve cognitive function over 12–24 months. However, the OmegAD trial (2006, Archives of Neurology, n=204) found that DHA supplementation slowed cognitive decline in patients with very mild Alzheimer's disease but not in those with moderate-to-advanced disease. The pattern suggests that omega-3s may be protective when started early — before significant neurodegeneration — but cannot reverse established disease. This distinction between prevention and treatment is critical and often lost in popular coverage.
Inflammation Resolution: A Paradigm Shift
The anti-inflammatory effects of omega-3s are mechanistically well-understood, but a discovery by Dr. Charles Serhan, professor of anesthesia at Harvard Medical School and Brigham and Women's Hospital, reframed how researchers think about them entirely. In the early 2000s, Serhan discovered a new class of molecules produced from EPA and DHA: specialized pro-resolving mediators (SPMs), which include resolvins, protectins, and maresins.
The paradigm shift: inflammation was previously understood as a process that could be either activated or suppressed. Serhan's work showed that resolution of inflammation is an active process — not the passive absence of inflammatory signals — and that EPA and DHA are the biochemical precursors of the molecules that drive this active resolution. Resolution involves clearing cellular debris, reducing neutrophil infiltration, and restoring tissue homeostasis. Without adequate EPA and DHA, the resolution pathways are impaired, and inflammation that should resolve in days persists for weeks or months — potentially contributing to the chronic low-grade inflammation implicated in cardiovascular disease, metabolic syndrome, and neurodegeneration.
Practical Guide: Forms, Doses, and Quality
Fish oil (triglyceride or ethyl ester form): The most common supplement form. Triglyceride-form fish oil has approximately 50% better absorption than ethyl ester form, according to a 2010 Prostaglandins, Leukotrienes and Essential Fatty Acids study (n=72, led by Dr. Jorn Dyerberg, the Danish physician who first documented the cardiovascular benefits of omega-3s in Greenlandic Inuit populations). Look for "triglyceride form" on the label or supplement facts page.
Algae oil: The only plant-based source of preformed DHA and EPA. Algae are the original producers of omega-3s in the marine food chain — fish accumulate them by eating algae or algae-eating organisms. Algal oil supplements are vegan, sustainable, and free of the mercury and PCB contamination concerns associated with fish oil. A 2014 Journal of the Academy of Nutrition and Dietetics study (n=32, led by Dr. Carol Geppert) confirmed that algal DHA raises blood DHA levels equivalently to fish oil at matched doses.
Dosing recommendations: For general health maintenance, 500–1,000 mg combined EPA+DHA daily — achievable through two servings of fatty fish per week (salmon, mackerel, sardines, herring) or supplementation. For cardiovascular risk reduction in individuals with elevated triglycerides or established cardiovascular disease, 2–4 g daily under medical supervision. Dr. Harris recommends measuring the Omega-3 Index (a simple blood test, available through standard labs) to establish a baseline and guide individual dosing — target: above 8%.
Quality: Fish oil oxidation is a real concern. Rancid fish oil not only loses efficacy but may produce harmful oxidation byproducts. A 2015 Scientific Reports analysis of 32 fish oil supplements from New Zealand found that the majority exceeded recommended oxidation limits. Third-party certification from IFOS (International Fish Oil Standards), USP, or NSF International provides independent verification of purity, potency, and oxidation levels. Store fish oil supplements in the refrigerator after opening, and discard any product that smells strongly fishy — fresh omega-3 oil should have minimal odor.